Adding a second HER2 blocker may lower chance of invasive breast cancer for some women
Monday, June 5, 2017 - 14:42
in Health & Medicine
A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest.